Metformin (for longevity)
Compare this record with another, side by side →
How this letter has changedLatest: August 2026 · First graded.
Metformin is the most-cited longevity drug and had no graded record on EBL. It has one now, and the letter is D. Walton et al. (PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 31557380, the MASTERS trial) randomized 94 adults aged 65 and over without diabetes to metformin 1,700 mg/day or placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. through 14 weeks of progressive resistance training. The stated hypothesis was that metformin would augment the muscle response; it blunted it. Konopka et al. (PMID 30548390) found metformin inhibited the mitochondrial adaptations to aerobic training in the same population. TAME, the trial designed to test metformin against age-related disease, has not reported, and the observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. survival signal is not randomized. So the D is Route 2 Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale.: tested in humans on the actual molecule, in the target population, result adverse on the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. that matters.PMID 31557380 PMID 30548390
Every change to a letter on this site is dated and published. The full evidence log →
Metformin is a common diabetes drug promoted for slowing aging. Two studies gave it to healthy older adults who were also doing supervised exercise. In both, metformin made the exercise less effective. People gained less muscle and fitness than those on a dummy pill. So in healthy older adults, it worked against the benefits of exercise.
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
Why this gradeGrade D, tested, harm found. The reasoning, and what the grade does not cover.
Grade D on Route 2: tested, harm found. This is not a null result and it is not an absence of evidence. Two randomized trials put metformin into healthy older adults alongside supervised exercise, and both found it reduced the benefit of the training rather than adding to it. Walton pre-specified that metformin would augment the muscle response to 14 weeks of progressive resistance training and reported it blunted the hypertrophic response instead. Konopka reported metformin inhibited the mitochondrial adaptations aerobic training normally produces. Resistance training holds EBL's only exercise Grade A, and it is one of the two it interfered with.
WHAT THIS GRADE DOES NOT COVERthis grades metformin taken for longevity by people who do not have diabetes. It says nothing about metformin prescribed for type 2 diabetes, where it is standard care, and nothing here is a basis for changing a prescribed medication. It also does not cover the question TAME was built to ask, whether metformin delays age-related disease, because TAME has not reported. The observational finding that metformin users outlive matched non-diabetic controls is not randomized and carries no letter here.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Grade D, tested: in a human randomized trial, the treated group did worse on the endpoint graded. How to read a grade →
See the full evidence record →This was not skipped. A human randomized trial has tested it and did not find a benefit on the endpoint below. That is a different statement from an untested intervention, which may still turn out to work. A Route 1 No human randomized trial has been run, so the record rests on animal or mechanistic evidence only. One of the two routes to the lowest letter on EBL's scale. Grade D means nobody has looked. A Route 2 Grade D means somebody looked and the answer was no.
Population 94 healthy adults aged 65 and over without diabetes, metformin 1,700 mg/day or placebo, 14 weeks
Certainty Moderate. Randomized, double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends., placebo-controlled, multicenter. The hypothesis was that metformin would AUGMENT the muscle response. It did the opposite: the authors report metformin blunted the hypertrophic response to training.
PMID 31557380 →
Population Older adults without diabetes, metformin or placebo during supervised aerobic training
Certainty Moderate. Randomized controlled trial People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect.. Metformin inhibited the mitochondrial adaptations exercise normally produces, consistent with the earlier finding that it antagonizes exercise-induced gains in insulin sensitivity and cardiorespiratory fitness.
PMID 30548390 →
The trial that would change this grade.
A positive trial of this shape would move this entry to C.
Why the current trials fall short
The human case for metformin comes from people with diabetes, compared with people who were not assigned at random. The two randomized trials in healthy older adults found it reduced the benefit of exercise. No trial has tested it for aging in people without diabetes.
Why people believe itThree human sources; no published case reports of benefit; one report of harm.
The case for metformin as an anti-aging drug comes from people with diabetes: those taking it live as long as, or longer than, comparable people without diabetes. It also extended lifespan in one mouse study, though not in the larger three-site program that tested it later.
What supporters point to, and what each source actually shows. None of it is enough to move this letter higher; the trial described above under Evidence wanted is what would.
- Population study, not a trialIn UK health records, people with diabetes started on metformin survived longer than matched people without diabetes. An observational comparison; the groups were not assigned at random. PMID 25041462
- Population study, not a trialA review of 53 studies found lower death and cancer rates in metformin users. The authors note the groups differed at the start in ways that could bias the result. PMID 28802803
- Human trial, a different useIn overweight people with type 2 diabetes (UKPDS 34), metformin reduced deaths compared with diet alone. A trial in diabetes, not in healthy aging. PMID 9742977
A case report describes what happened to one or a few patients. It cannot show the treatment caused the change, and reports of success are published more often than reports of failure.
A PubMed search in October 2026 found no published case report of benefit for this use.
- Lactic acidosis, a serious complication, in an 82-year-old man with kidney disease taking metformin for diabetes. PMID 39036128
Searched PubMed, October 2026: 5 case report record(s) returned. None describes benefit from metformin taken for aging. One reports harm and is listed.
Animal and laboratory workTwo studies in animals or cells. Not counted toward the letter.
None of this is human evidence and none of it counts toward the letter. It is listed so the reader can see what the idea rests on. Most findings in animals do not hold up when tested in people.
- MouseMetformin started at middle age extended healthspan and lifespan in male mice at a low dose; a higher dose was toxic. PMID 23900241
- MouseIn the National Institute on Aging's three-site testing program, metformin alone did not significantly extend lifespan in mice. PMID 27312235
Tested in healthy older adults, twice, alongside the intervention EBL grades highest. Both trials found metformin reduced the benefit of exercise rather than adding to it.
Tested in humans on the actual molecule, and the result was null or adverse on the endpoint that matters.
Metformin 1,700 mg/day by mouth for 14 weeks alongside supervised progressive resistance training (Walton 2019; PMID 31557380), and metformin alongside 12 weeks of supervised aerobic training (Konopka 2019; PMID 30548390). Both trials enrolled adults aged 65 and over WITHOUT diabetes. The dose is the standard glycemic dose; no separate 'longevity dose' has been tested.
Prescription only; requires physician management. This record grades metformin as a longevity intervention in people who do not have diabetes. It says nothing about metformin prescribed for type 2 diabetes, where it is standard care.
In healthy older adults, metformin reduced the benefit of exercise rather than adding to it. MASTERS found the placebo group gained more lean body mass and more thigh muscle than the metformin group across 14 weeks of resistance training, and a separate trial found metformin attenuated the gains in insulin sensitivity and VO2 max The most oxygen the body can use during all-out exercise, a standard measure of aerobic fitness. from 12 weeks of aerobic training. Long-term use also depletes vitamin B12.
- PMID 31557380 →Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial.
- PMID 30548390 →Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults.
- PMID 33071237 →Metformin alters skeletal muscle transcriptome adaptations to resistance training in older adults.
This record grades the drug's own longevity evidence. What metformin does to nutrient status is a separate question, answered on the metformin depletion A fall in a nutrient's level caused by a medication, for example through reduced absorption or increased loss. record.
Depletion record →Primary evidenceThree papers, each linked to its PubMed record.
Walton et al. (Aging Cell, 2019; PMID 31557380): randomized, double-blind, placebo-controlled multicenter trial, 94 healthy adults aged 65 and over without diabetes, metformin 1,700 mg/day or placebo through 14 weeks of progressive resistance training. The pre-specified hypothesis was that metformin would AUGMENT the muscle response to training. It did not; metformin blunted the training-induced hypertrophy. Konopka et al. (Aging Cell, 2019; PMID 30548390): randomized controlled trial in older adults, metformin inhibited the mitochondrial adaptations to aerobic exercise training. Kulkarni et al. (Aging (Albany NY), 2020; PMID 33071237) is the muscle transcriptome analysis of the Walton cohort and is cited for mechanism, not for the grade. TAME, the trial designed to test metformin against age-related disease, has not reported. The observational signal that people taking metformin outlive matched non-diabetic controls is not randomized and does not move a grade here. So the position is not that metformin is untested: it is that the two randomized trials that put it in the aging population both found it reduced the benefit of resistance and aerobic training, and resistance training is the intervention holding EBL's only exercise Grade A. Route 2: tested in humans on the actual molecule, result adverse.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →